理解免疫接种后不良事件:3年监测中疫苗安全性与偶合事件的证据
该队列事件监测研究在儿童中评估UIP疫苗接种后不良事件(AEFI)的发生率与预测因素,采用主动电话随访与被动报告相结合的方式。结果显示AEFI发生率为10.37%,严重反应需住院者为3.47%(1.27事件/1000剂次),五联疫苗发生率最高(19.21%),口服脊灰疫苗最低(0.13%)。作者结论认为UIP儿童疫苗安全性良好,严重反应不常见,需与偶合反应鉴别。
要点
- AEFI总发生率为10.37%,严重反应需住院者为3.47%(1.27事件/1000剂次)。
- 五联疫苗AEFI发生率最高(19.21%),口服脊灰疫苗最低(0.13%)。
- 最常见反应为发热(23.75事件/1000剂次)和注射部位疼痛(4.98事件/1000剂次)。
核心结论
- UIP所含儿童疫苗显示良好的安全性特征,严重反应不常见,强调需 thorough 调查与清晰沟通以区分偶合反应。
研究设计与样本
- 采用队列事件监测研究设计,在研究现场识别接受至少一剂UIP儿童疫苗的儿童中的AEFI。
- 监测包括主动监测(电话随访)和被动监测(来自医务人员报告)。
- 使用2检验评估AEFI的潜在预测因素,并计算相对风险。
主要发现
- AEFI发生率为10.37%,其中3.47%(1.27事件/1000剂次)为严重反应需住院。
- 五联疫苗(白喉、破伤风、百日咳、乙肝、Hib)AEFI发生率最高,为19.21%(218事件/1000剂次);口服脊灰疫苗最低,为0.13%(1.32事件/1000剂次)。
- 主动报告事件为34.83事件/1000剂次,被动报告事件为1.69事件/1000剂次。
- 最常见反应为发热(23.75事件/1000剂次),其次为注射部位疼痛(4.98事件/1000剂次)。
- 报告1例五联疫苗接种后死亡,后判定为偶合事件;90.62%的反应为疫苗产品相关,4.76%为偶合,2.70%为免疫差错相关,0.39%为不确定。
关键数值与推荐
- AEFI预测因素包括儿科人群、延迟免疫、营养缺乏、儿童共病状态以及来自富裕家庭的儿童。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background Periodic vaccine safety checks are a crucial component of any country’s pharmacovigilance system. Unwanted reactions following childhood vaccination are unacceptable to the public, making rapid safety checks and alerts essential for maintaining public confidence. Objectives The study evaluates the safety of childhood vaccines in the paediatric population through active surveillance and explores various predictors for the development of adverse event following immunisation (AEFI) based on population characteristics. Methodology A cohort event monitoring study was designed to identify AEFIs in children receiving at least one childhood vaccine under the Universal Immunisation Programme (UIP) at the study site. Both active surveillance (via telephone follow-up calls) and passive surveillance (from healthcare workers) were included. Potential predictors of AEFIs were evaluated using the 2 test, and relative risk was calculated. Results The study estimated an AEFI incidence rate of 10.37%, with 3.47% (1.27 events/1000 doses) being serious reactions requiring hospitalisation. The highest incidence was with the Pentavac vaccine (diphtheria, tetanus, pertussis, hepatitis B, Hib) at 19.21% (218 events/1000 doses), while the lowest incidence was observed with the oral polio vaccine at 0.13% (1.32 events/1000 doses). Most reported Adevrse Events were solicited (34.83 events/1000 doses), while unsolicited events accounted for 1.69/1000 doses. The most common reaction was fever (23.75 events/1000 doses), followed by pain at injection site (4.98 events/1000 doses). One death following Pentavac vaccination was reported but later deemed coincidental. Overall, 90.62% of the reactions were vaccine product-related, 4.76% coincidental, 2.70% immunisation error-related and 0.39% were indeterminate. Predictors of AEFIs included paediatric population, delayed immunisation, nutritional deficiencies and comorbid status of the child and children from affluent families. Conclusion Childhood vaccines included in the UIP have shown a favourable safety profile. Serious reactions are infrequent, emphasising the need for thorough investigation and clear communication to differentiate them from coincidental reactions, which can occur more frequently in this age group.
引用
- BMJ Paediatrics Open:Understanding adverse events following immunisation: evidence of vaccine safety and coincidental events from 3 years of surveillance
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。